Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody... Show more
A.I.dvisor indicates that over the last year, CBIO has been loosely correlated with SMMT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CBIO jumps, then SMMT could also see price increases.
| Ticker / NAME | Correlation To CBIO | 1D Price Change % | ||
|---|---|---|---|---|
| CBIO | 100% | -1.53% | ||
| SMMT - CBIO | 43% Loosely correlated | -6.14% | ||
| EDIT - CBIO | 37% Loosely correlated | +1.40% | ||
| STRO - CBIO | 37% Loosely correlated | +2.40% | ||
| UTHR - CBIO | 36% Loosely correlated | -0.36% | ||
| MGTX - CBIO | 36% Loosely correlated | +4.44% | ||
More | ||||
| Ticker / NAME | Correlation To CBIO | 1D Price Change % |
|---|---|---|
| CBIO | 100% | -1.53% |
| biopharmaceuticals theme (43 stocks) | 38% Loosely correlated | -1.18% |
| drugs theme (211 stocks) | 36% Loosely correlated | -1.16% |
| biotechnology theme (199 stocks) | 35% Loosely correlated | -1.21% |
a clinical stage biopharmaceutical company
Industry Biotechnology
The RSI Oscillator for CBIO moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In 36 of the 38 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CBIO as a result. In 85 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for CBIO just turned positive on October 21, 2026. Looking at past instances where CBIO's MACD turned positive, the stock continued to rise in 32 of 38 cases over the following month. The odds of a continued upward trend are 84%.
Following a +8.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBIO advanced for three days, in 192 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 52 cases where CBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for CBIO moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CBIO broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CBIO entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.158) is normal, around the industry mean (3.498). CBIO has a moderately low P/E Ratio (-96.714) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (35.461) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 52 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.